Related Experiment Video

Updated: Aug 1, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells

K Sundarapandiyan1, T Keler, D Behnke

  • 1Medarex Inc., 1545 Route 22 East, Annandale, N J08801, USA .

Journal of Immunological Methods
|February 27, 2001
PubMed

Insights

Two novel bispecific molecules (BSMs) targeting CD30 effectively triggered myeloid effector cells for potent anti-lymphoma activity in vitro. These BSMs demonstrated significant antibody-dependent cell-mediated cytotoxicity and enhanced phagocytosis of CD30-expressing tumor cells.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • CD30 is a tumor antigen overexpressed on Hodgkin's lymphoma cells, making it a promising target for immunotherapy.
  • Bispecific molecules (BSMs) offer a strategy to engage immune effector cells against cancer cells.

Purpose of the Study:

  • To evaluate the in vitro efficacy of two novel BSMs designed to target CD30 and activate myeloid effector cells.
  • To assess the ability of these BSMs to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis against CD30-expressing lymphoma cells.

Main Methods:

  • Two BSMs were constructed: H22xKi-4 (targeting CD30 and CD64/FcgammaRI) and A77xKi-4 (targeting CD30 and CD89/FcalphaR).
  • In vitro binding assays were performed using lymphoma cell lines and myeloid effector cells.
  • ADCC assays were conducted using human monocytes, polymorphonuclear leukocytes (PMNs), and whole blood as effector cells.
  • Phagocytosis assays utilized monocyte-derived macrophages (MDMs).

Main Results:

  • Both H22xKi-4 and A77xKi-4 BSMs specifically bound to CD30-expressing lymphoma cells and their respective Fc receptors (CD64 and CD89).
  • BSMs mediated potent, dose-dependent ADCC of CD30+ tumor cells by human monocytes.
  • A77xKi-4 BSM also showed ADCC activity with PMNs and whole blood effectors in some experiments.
  • Both BSMs significantly enhanced MDM-mediated phagocytosis of CD30+ tumor cells.

Conclusions:

  • Targeting CD30 with BSMs that engage myeloid Fc receptors (FcgammaRI and FcalphaR) results in potent in vitro anti-tumor activity.
  • These BSMs represent a promising immunotherapeutic strategy for CD30-expressing lymphomas.
  • The findings support further investigation of these BSMs in preclinical and clinical settings.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...